ECSP055606A - Composiciones farmacéuticas para la administración porvía oral de medicamentos analgésicos - Google Patents

Composiciones farmacéuticas para la administración porvía oral de medicamentos analgésicos

Info

Publication number
ECSP055606A
ECSP055606A EC2005005606A ECSP055606A ECSP055606A EC SP055606 A ECSP055606 A EC SP055606A EC 2005005606 A EC2005005606 A EC 2005005606A EC SP055606 A ECSP055606 A EC SP055606A EC SP055606 A ECSP055606 A EC SP055606A
Authority
EC
Ecuador
Prior art keywords
administration
analgesic
oral
pharmaceutical compositions
narcotic analgesic
Prior art date
Application number
EC2005005606A
Other languages
English (en)
Inventor
Pankaj Modi
Original Assignee
Generex Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generex Pharm Inc filed Critical Generex Pharm Inc
Publication of ECSP055606A publication Critical patent/ECSP055606A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona un nuevo planteamiento del tratamiento del dolor avanzado, con una composición farmacológica constituida por un analgésico narcótico, un alquilsulfato de metal alcalino, un agente isotónico, un éter de polioxietileno y una sal biliar, en un solvente adecuado. El analgésico narcótico está presente en forma micelar, con un tamaño de micela de aproximadamente 1-10 nanómetros (nm). La formulación farmacéutica permite la administración de un analgésico narcótico por la boca del paciente, a través de la mucosa bucal, mediante un aerosol, y proporciona un método de tratamiento sin inyecciones para la administración de narcóticos y fármacos analgésicos.
EC2005005606A 2002-08-16 2005-02-16 Composiciones farmacéuticas para la administración porvía oral de medicamentos analgésicos ECSP055606A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/222,699 US6849263B2 (en) 1998-12-21 2002-08-16 Pharmaceutical compositions for buccal delivery of pain relief medications

Publications (1)

Publication Number Publication Date
ECSP055606A true ECSP055606A (es) 2005-04-18

Family

ID=31886628

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005606A ECSP055606A (es) 2002-08-16 2005-02-16 Composiciones farmacéuticas para la administración porvía oral de medicamentos analgésicos

Country Status (9)

Country Link
US (1) US6849263B2 (es)
EP (1) EP1556004A2 (es)
JP (1) JP2005538136A (es)
BR (1) BR0313451A (es)
CA (1) CA2494147A1 (es)
EC (1) ECSP055606A (es)
MX (1) MXPA05001886A (es)
NZ (1) NZ537864A (es)
WO (1) WO2004016244A2 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60142043D1 (de) * 2000-04-03 2010-06-17 Battelle Memorial Inst Columbu Ausgabevorrichtungen und flüssigformulierungen
JP2004526674A (ja) * 2000-12-01 2004-09-02 バテル・メモリアル・インスティテュート 液体処方物中における生体分子の安定化のための方法
US7244703B2 (en) 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
CA2486801A1 (en) * 2002-05-21 2003-11-27 Anadis Ltd Method of prophylaxis of infection
JP2006519770A (ja) * 2003-03-11 2006-08-31 アラキス リミテッド 新規組成物
US20060062812A1 (en) * 2003-03-11 2006-03-23 Calvin Ross Novel compositions
CN101829319A (zh) 2003-12-08 2010-09-15 Cpex药品公司 用于胰岛素治疗的药用组合物及方法
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
US7754230B2 (en) * 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
MXPA06013437A (es) * 2004-05-19 2007-03-23 Los Angeles Biomed Res Inst Uso de un detergente para la eliminacion no quirurgica de grasa.
ES2490595T3 (es) * 2005-02-17 2014-09-04 Abbott Laboratories Administración transmucosal de composiciones de fármacos para tratar y prevenir trastornos en animales
WO2006105205A1 (en) * 2005-03-29 2006-10-05 University Of Kentucky Research Foundation Sublingual spray for the treatment of pain
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
US8623401B2 (en) * 2008-03-27 2014-01-07 Fenwafe Inc. Wafer formulation
US20090263476A1 (en) * 2008-04-16 2009-10-22 Jobdevairakkam Christopher N Composition of Rapid Disintegrating Direct Compression Buccal Tablet
WO2010045599A1 (en) * 2008-10-17 2010-04-22 Pharmacofore, Inc. Pharmaceutical compositions with attenuated release of phenolic opioids
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
GB2477545B (en) * 2010-02-05 2011-12-21 Special Products Ltd A liquid morphine composition for buccal administration
US20130059914A1 (en) 2010-04-21 2013-03-07 Signature Therapeutics, Inc. Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof
US20110262355A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
GB2481619B (en) * 2010-06-30 2012-06-20 Londonpharma Ltd Formulations and delivery devices for the sublingual administration of opioids
AU2012205733B2 (en) 2011-01-11 2015-10-08 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
MX363465B (es) 2011-02-18 2019-03-25 Kythera Biopharmaceuticals Inc Tratamiento de la grasa submental.
WO2012122420A2 (en) 2011-03-09 2012-09-13 Pharmacofore, Inc. Opioid prodrugs with heterocyclic linkers
JP6148182B2 (ja) 2011-03-09 2017-06-14 シグネーチャー セラピューティクス, インク.Signature Therapeutics, Inc. 複素環式リンカーを有する活性薬剤プロドラッグ
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
RU2657523C2 (ru) * 2011-11-03 2018-06-14 Олег Петрович Жирнов Фармацевтический аэрозольный состав ингибиторов протеаз с озон-сберегающим пропеллентом и его получение
US20220226240A1 (en) * 2016-03-03 2022-07-21 Ctt Pharma Inc. Orally administrable composition
US11166912B2 (en) * 2016-03-03 2021-11-09 Ctt Pharma Inc. Orally administrable composition
US11298336B2 (en) 2019-05-30 2022-04-12 Soluble Technologies, Inc. Water soluble formulation
US11786475B2 (en) 2020-07-22 2023-10-17 Soluble Technologies Inc. Film-based dosage form
IL305493A (en) 2021-03-09 2023-10-01 Ensysce Biosciences Inc Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof
CA3230025A1 (en) 2021-09-29 2023-04-06 Lynn Kirkpatrick Enzyme-cleavable methadone prodrugs and methods of use thereof

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53107408A (en) * 1977-02-28 1978-09-19 Yamanouchi Pharmaceut Co Ltd Micellar preparation for rectal infusion
US4900730A (en) * 1981-01-14 1990-02-13 Toyo Jozo Co., Ltd. Preparation which promotes the absorption of peptides
NL193099C (nl) * 1981-10-30 1998-11-03 Novo Industri As Gestabiliseerde insuline-oplossing.
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
JPH0753661B2 (ja) * 1984-03-08 1995-06-07 フアレス フアーマスーチカル リサーチ エヌブイ プロ―リポソーム組成物及びリポソームの水性分散物を作る方法
GB8430346D0 (en) * 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
IL78425A (en) 1985-04-15 1991-05-12 Lilly Co Eli Intranasal formulation containing insulin
DK179286D0 (da) * 1986-04-18 1986-04-18 Nordisk Gentofte Insulinpraeparat
US4673679A (en) * 1986-05-14 1987-06-16 E. I. Du Pont De Nemours And Company Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
US5690954A (en) * 1987-05-22 1997-11-25 Danbiosyst Uk Limited Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
GB8900267D0 (en) * 1989-01-06 1989-03-08 Riker Laboratories Inc Narcotic analgesic formulations and apparatus containing same
US5174988A (en) * 1989-07-27 1992-12-29 Scientific Development & Research, Inc. Phospholipid delivery system
CA2033725C (en) * 1990-01-24 2001-05-29 Folker Pittrof Pharmaceutical and cosmetic compositions containing a salt of cholanic acid
GB9007052D0 (en) * 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
ATE143603T1 (de) * 1990-03-30 1996-10-15 Yasunori Morimoto Transdermal absorbierbares mittel mit morphin hydrochlorid
US5230884A (en) * 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
US5292499A (en) * 1990-09-11 1994-03-08 University Of Wales College Of Cardiff Method of preparing medical aerosol formulations including drug dissolved in reverse micelles
US5416071A (en) * 1991-03-12 1995-05-16 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release containing epo and hyaluronic acid
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
IT1255449B (it) * 1992-06-30 1995-10-31 Fabio Berlati Uso di nor- e omo-derivati di acidi biliari come promotori di assorbimento di farmaci.
US5981591A (en) * 1992-12-04 1999-11-09 Mayor Pharmaceutical Laboratories, Inc. Sprayable analgesic composition and method of use
ES2107203T3 (es) * 1993-03-17 1997-11-16 Minnesota Mining & Mfg Una formulacion de aerosol que contiene un adyuvante de dispersion derivado de un diol-diacido.
ES2122261T3 (es) * 1993-03-17 1998-12-16 Minnesota Mining & Mfg Formulacion de aerosol que contiene un adyuvante de dispersion derivado de un ester, una amida o un mercaptoester.
US5492688A (en) * 1993-04-28 1996-02-20 The Center For Innovative Technology Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable suspending, solubilizing, wetting, emulsifying or lubricating agent
US5747445A (en) * 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
US5514670A (en) * 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5451408A (en) * 1994-03-23 1995-09-19 Liposome Pain Management, Ltd. Pain management with liposome-encapsulated analgesic drugs
JP2740153B2 (ja) * 1995-03-07 1998-04-15 エフ・ホフマン−ラ ロシユ アーゲー 混合ミセル
US5653987A (en) * 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
PL323931A1 (en) 1995-06-07 1998-04-27 Alliance Pharma Compositions of reversed emulsion of fluorine derivatives of hydrocarbons for use as drug delivering carriers
ES2234010T3 (es) * 1996-04-12 2005-06-16 Novadel Pharma Inc. Aerosol bucal polar.
US5891465A (en) 1996-05-14 1999-04-06 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
WO1998002186A1 (en) * 1996-07-11 1998-01-22 Farmarc Nederland B.V. Inclusion complex containing indole selective serotonin agonist
US6214375B1 (en) * 1996-07-16 2001-04-10 Generex Pharmaceuticals, Inc. Phospholipid formulations
US6090407A (en) * 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
IL122084A (en) 1997-10-31 1999-09-22 Lurident Ltd Formulation for personal care with mucoadhesive properties
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
US6350458B1 (en) * 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US6221378B1 (en) 1998-02-10 2001-04-24 Generex Pharmaceuticals Incorporated Mixed micellar delivery system and method of preparation
US6193997B1 (en) * 1998-09-27 2001-02-27 Generex Pharmaceuticals Inc. Proteinic drug delivery system using membrane mimetics
US6261539B1 (en) * 1998-12-10 2001-07-17 Akwete Adjei Medicinal aerosol formulation
US6451286B1 (en) * 1998-12-21 2002-09-17 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds
US6312665B1 (en) * 1998-12-21 2001-11-06 Generex Pharmaceuticals Incorporated Aerosol formulations for buccal and pulmonary application
US6436367B1 (en) * 1998-12-21 2002-08-20 Generex Pharmaceuticals Inc. Aerosol formulations for buccal and pulmonary application
US6271200B1 (en) * 1998-12-21 2001-08-07 Generex Pharmaceuticals Inc. Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles
US6375975B1 (en) * 1998-12-21 2002-04-23 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary application
WO2000047203A1 (en) 1999-02-12 2000-08-17 Mqs, Inc. Formulation and system for intra-oral delivery of pharmaceutical agents
US6485706B1 (en) * 1999-06-04 2002-11-26 Delrx Pharmaceutical Corp. Formulations comprising dehydrated particles of pharma-ceutical agents and process for preparing the same
US6225343B1 (en) * 1999-06-16 2001-05-01 Nastech Pharmaceutical Company, Inc. Compositions and methods comprising morphine gluconate
WO2002045713A2 (en) * 2000-12-04 2002-06-13 Sepracor, Inc. Orally-bioavailable formulations of fentanyl and congeners thereof

Also Published As

Publication number Publication date
WO2004016244A3 (en) 2004-05-21
MXPA05001886A (es) 2005-06-03
US20030035831A1 (en) 2003-02-20
CA2494147A1 (en) 2004-02-26
JP2005538136A (ja) 2005-12-15
WO2004016244A2 (en) 2004-02-26
US6849263B2 (en) 2005-02-01
EP1556004A2 (en) 2005-07-27
NZ537864A (en) 2008-01-31
BR0313451A (pt) 2005-07-12

Similar Documents

Publication Publication Date Title
ECSP055606A (es) Composiciones farmacéuticas para la administración porvía oral de medicamentos analgésicos
ES2414084T3 (es) Sistema de administración de fármacos por vía transmucosa
DK2574167T3 (en) LIQUID NOSE SPRAY CONTAINING low-dose naltrexone
JP2004501181A (ja) 粘膜の痛みを治療するための方法および組成物
CA2536582A1 (en) Intranasal opioid compositions
MX2009009131A (es) Mejoras en y con relacion a composiciones medicinales.
US12303597B2 (en) Naloxone formulations for sublingual and/or buccal administration
US20240216360A1 (en) Drug products for intranasal administration and uses thereof
JP5584713B2 (ja) アズレンスルホン酸ナトリウムを主剤とする点鼻薬
WO2020033402A1 (en) Drug products for nasal administration and uses thereof
BRPI0412430A (pt) polipeptìdeo agonista do receptor de zot e zonulina
MXPA04010860A (es) Composiciones terapeuticas de 1,2,3,6-tetrahidropirimidin-2-ona y metodos para usarla.
EP1648430A1 (en) Treatment of premature ejaculation
RU2552290C1 (ru) Соединения опиоидных антагонистов и их применение при лечении склеродермии
US20210213009A1 (en) Methods of treating pain
JP2002205942A (ja) 局所適用組成物
JP2007008831A (ja) 口内炎治療のための口腔用組成物
UA93365C2 (ru) Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты)
JP2002161032A (ja) 粘膜適用組成物
JP2005075735A (ja) オキシメタゾリン含有組成物
Reddy et al. Role of dexamethasone in reducing postoperative sequelae following impacted mandibular third molar surgery: A comparative clinical study
ITMI980356A1 (it) Composizioni orali a basso dosaggio di proteine citotossiche
Bujedo et al. Fentanyl in a pectin gel treating breakthrough pain in vertebral compression fracture due to multiple myeloma: A descriptive study of three cases
CN118414154A (zh) 泛bet抑制剂的用途
TW202519195A (zh) 苯酚衍生物的溶液型藥物組合物及其製劑和用途